The FDA wants these cold medicines off the shelves. Should Canada follow?
The FDA has proposed removing phenylephrine, a common ingredient in decongestants, due to its ineffectiveness, which may ...
Medscape1d
GLP-1 Prescribing Decisions: Compounded or Brand-Name?
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
Targets the reduction in CABG-related bleeding severity due to the blood thinning drug, ticagrelor – a major unmet medical need in heart attack ...
MM&M8d
Rx Rundown: Avid Bioservices, Novo Nordisk, Zealand Pharma and more
Ascendis Pharma and Novo Nordisk announced a partnership to develop cardiovascular and metabolic drugs that utilize ... said ...
Why the AirPods Pro’s best new feature is forbidden in over 100 countries
Apple's new hearing health features for the AirPods Pro could be a game-changer for those with hearing loss, but half of all ...
Stockhouse24d
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery ...
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...
Medexus Announces Strong Fiscal Q2 2025 Results
Detailed price information for Medexus Pharmaceuticals Inc (MDP-T) from The Globe and Mail including charting and trades.
T-Net9d
Eupraxia Closes $44.5M Private Placement Financing, Appoints Former Brookfield Senior Partner to Board
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...
The American Journal of Managed Care15d
Canada Less Likely to Have Meaningful Drug Shortages Due to Supply Chain Issues
Drugs with a ... reported to either the FDA or Health Canada, depending on location. IQVIA’s Multinational Integrated Data Analysis (MIDAS) data were used for this study, which includes 89% of US drug ...
PMPRB report reviews new drugs and their potential impact on future drug spending in Canada
The latest edition of Meds Pipeline Monitor, from the Patented Medicine Prices Review Board, provides stakeholders with a list of new medicines in the late stages of clinical evaluation that may ...
Joplin Globe11d
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...